Eisai, Biogen

The U.S. Food and Drug Administration (FDA) officially approved the new drug “lecanemab” for dementia developed by Eisai and US Biogen on the 6th. This is the first pharmaceutical product to prove the effect of slowing the progression of the disease. In the future, the American public health insurance “Medicare” for the elderly will be selected as covered by insurance, and rapid spread is expected.